Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4).’ The study aims to assess the safety, tolerability, and efficacy of odronextamab in patients with aggressive B-cell non-Hodgkin lymphoma that has relapsed or is refractory.
The intervention being tested is odronextamab, an experimental bispecific antibody designed to target CD20 and CD3, administered as a monotherapy. It is compared to standard of care therapies, which include various drug combinations and potentially an autologous stem cell transplant.
The study follows a randomized, parallel assignment model without masking, focusing on treatment as the primary purpose. This design allows for a direct comparison between odronextamab and standard care in terms of safety and efficacy.
The study began on February 15, 2024, with the latest update on August 7, 2025. These dates are crucial as they indicate the study’s progression and the timeline for potential results.
This clinical update could positively influence Regeneron’s stock performance and investor sentiment, especially if odronextamab shows promising results. The competitive landscape in the treatment of aggressive B-cell non-Hodgkin lymphoma could see shifts depending on the outcomes of this study.
The study is ongoing, with further details available on the ClinicalTrials portal.